Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 1996

Study Completion Date

August 31, 2007

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
DRUG

dexamethasone

DRUG

doxorubicin hydrochloride

DRUG

idarubicin

DRUG

vincristine sulfate

Trial Locations (12)

B9 5SS

Birmingham Heartlands Hospital, Birmingham

CB2 2QQ

Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge

L7 8XP

Royal Liverpool and Broadgreen Hospitals NHS Trust, Liverpool

WV10 0QP

New Cross Hospital, Wolverhampton

BT9 7AB

Centre for Cancer Research and Cell Biology at Belfast City Hospital, Belfast

AB25 2ZN

Aberdeen Royal Infirmary, Aberdeen

G83 0UA

Vale Of Leven D G Hospital, Alexandria

DG1 4AP

Dumfries Royal Infirmary, Dumfries

DD1 9SY

Ninewells Hospital and Medical School, Dundee

G11 6NT

West of Scotland Cancer Centre, Glasgow

G4 0SF

Royal Infirmary - Castle, Glasgow

Unknown

Royal Alexandra Hospital, Paisley

All Listed Sponsors
lead

West of Scotland Lymphoma Group

OTHER

NCT00006232 - Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma | Biotech Hunter | Biotech Hunter